AGENUS INC Investment Income, Interest
AGENUS INC (AGEN) reported Investment Income, Interest of $121.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-07
- AGENUS INC investment income, interest for the quarter ending 2026-06-30 was $121.00K, a 124.07% increase year-over-year.
- AGENUS INC investment income, interest for the quarter ending 2026-03-31 was $21.00K, a 88.83% decline year-over-year.
- AGENUS INC investment income, interest for the quarter ending 2025-12-31 was $30.00K, a 93.01% decline year-over-year.
- AGENUS INC investment income, interest for the quarter ending 2025-09-30 was $74.00K, a 92.74% decline year-over-year.
- AGENUS INC investment income, interest for fiscal 2025 was $345.00K, a 87.66% decline from fiscal 2024.
- AGENUS INC investment income, interest for fiscal 2024 was $2.79M, a 52.90% decline from fiscal 2023.
- AGENUS INC investment income, interest for fiscal 2023 was $5.93M, a 162.92% increase from fiscal 2022.
- AGENUS INC investment income, interest for fiscal 2022 was $2.26M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $121.00K 10-Q · filed 2026-08-07 | $141.00K 10-Q · filed 2026-08-07 | $172.00K derived: sum of 3 quarters · filed 2026-08-07 | $246.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $21.00K 10-Q · filed 2026-05-11 | $51.00K derived: sum of 2 quarters · filed 2026-05-11 | $125.00K derived: sum of 3 quarters · filed 2026-05-11 | $179.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $104.00K derived: sum of 2 quarters · filed 2026-03-16 | $158.00K derived: sum of 3 quarters · filed 2026-08-07 | $345.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | $74.00K 10-Q · filed 2025-11-10 | $128.00K derived: sum of 2 quarters · filed 2026-08-07 | $315.00K 10-Q · filed 2025-11-10 | $745.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $54.00K 10-Q · filed 2026-08-07 | $241.00K 10-Q · filed 2026-08-07 | $671.00K derived: sum of 3 quarters · filed 2026-08-07 | $1.69M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $188.00K 10-Q · filed 2026-05-11 | $617.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.64M derived: sum of 3 quarters · filed 2026-05-11 | $2.17M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $429.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.45M derived: sum of 2 quarters · filed 2026-03-16 | $1.99M derived: sum of 3 quarters · filed 2026-03-16 | $2.79M 10-K · filed 2026-03-16 |
| 2024-09-30 | $1.02M 10-Q · filed 2025-11-10 | $1.56M derived: sum of 2 quarters · filed 2025-11-10 | $2.37M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $539.00K 10-Q · filed 2025-08-11 | $1.35M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $808.00K 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $5.93M 10-K · filed 2026-03-16 | |||
| 2022-12-31 | $2.26M 10-K · filed 2025-03-17 | |||
| 2013-12-31 | $7.93K 10-K · filed 2014-03-07 | |||
| 2012-12-31 | $23.34K 10-K · filed 2014-03-07 | |||
| 2011-12-31 | $18.79K 10-K · filed 2014-03-07 | |||
| 2010-12-31 | $37.56K 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |